RankAlpha logo
Back to Rankings

OCS

OculisD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
OCS vs peer average
37/100
OCS vs. peer average (D vs. C)
Grade spread
A 1 · B 3 · C 1 · D 3 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

HROW is the first available peer comparator.

Ophthalmology-focused biotech with more direct eye-disease read-through than large-cap peers, though its commercial portfolio makes it a looser comp than OCS's late-stage pipeline.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerHROWHarrow
OCS
Oculis
HROW
Harrow
Grade
D
B
Momentum
4
19
Value
41
56
Sentiment
63
81
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs HROW

OCS / HROW
Grade Position
Below peers
OCS vs. peer average (D vs. C)
37/100
Momentum
4
HROW
Value
41
HROW
Sentiment
63
HROW

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs OCS
1
HROW
HROW
B
80/100
-2
2
GILD
GILD
B
80/100
-2
3
PHAT
Phathom Pharmaceuticals Inc Common
A
100/100
-3
4
CTMX
CytomX Therapeutics Inc Common
C
60/100
-1
5
RGNX
REGENXBIO Inc Common
D
40/100
Even
HROW is the first peer returned for this comparison set.